Everolimus
Who holds supplier records for Everolimus? 12 organisations hold a current record for Everolimus: an active US FDA Type II Drug Master File or a CEP. A further 1 organisation has only historical (inactive) DMF filings. 8 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (4), China (3), Spain (1), South (1) and 1 other country (1); not recorded for 2.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Everolimus: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/everolimus
Reading the evidence
- 12 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 5 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Everolimus expires 1 Jul 2028. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (12)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Everolimus. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Biocon LimitedIndiaCEPActive DMF 29657, 31950, 29651 · latest filing May 2018
- BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTDChinaCEPActive DMF 32020, 36661 · latest filing Dec 2021
- FARMHISPANIA SASpainCEPActive DMF 34295, 42323 · latest filing Oct 2025
- CHENGDU YACHT BIO-TECHNOLOGY CO LTDChinaActive DMF 29405, 39361 · latest filing Apr 2024
- CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTDCEP Company GMP cert on recordActive DMF 27216 · latest filing Jul 2013
- CKD BIO CORPSouthCEPActive DMF 34106 · latest filing Aug 2019
- CONCORD BIOTECH LTDIndiaCEP Company GMP cert on recordActive DMF 26350 · latest filing Jun 2013
- HANGZHOU HUADONG MEDICINE GROUP KANGRUN PHARMACEUTICAL CO LTDChinaActive DMF 26738 · latest filing Dec 2012
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 39412 · latest filing Mar 2024
- Natco PharmaIndia Company GMP cert on recordActive DMF 29696 · latest filing Sept 2015
- HISUN PHARMACEUTICAL HANGZHOU CO LTDCEP
- NetherlandsCEP Company GMP cert on record
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (8)
Certificates of Suitability on the EDQM register for Everolimus, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 13 certificates in total, including withdrawn, expired, suspended and repeat certificates.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| HISUN PHARMACEUTICAL (HANGZHOU) CO., LTD. Hangzhou City | CN | CEP 2024-314 - Rev 00 Everolimus, 0.2% BHT | Dec 2025 | — |
| FARMHISPANIA S.A. Montmeló | ES | CEP 2019-256 - Rev 03 Everolimus, 2.0% BHT | Sept 2025 | Inspected May 2023 Spain, outside 3-year window |
| CONCORD BIOTECH LIMITED Ahmedabad | IN | CEP 2022-106 - Rev 01 Everolimus, with 2% BHT | Sept 2025 | Inspected Jul 2025 Germany |
| SYNTHON B.V. Nijmegen | NL | CEP 2021-260 - Rev 01 Everolimus, BHT 2.0% | Feb 2024 | Inspected May 2024 Netherlands |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. Shu-Lin | TW | CEP 2021-192 - Rev 02 Everolimus, With antioxidant butylhydroxytoluene 2.0% | Feb 2024 | Inspected Apr 2024 Germany |
| BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. Suzhou | CN | CEP 2022-367 - Rev 00 Everolimus, Butylated hydroxytoluene 2.0% | Feb 2024 | — |
| CKD BIO CORPORATION Sapgyo-eup | KR | CEP 2019-321 - Rev 01 Everolimus, 2.0% BHT | Nov 2023 | — |
| BIOCON LIMITED Bengaluru | IN | R0-CEP 2020-072 - Rev 01 Everolimus, 2% BHT | Apr 2023 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (1)
Organisations whose Type II DMFs for Everolimus are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- Taiwan · Inactive DMF 29854 · filed Oct 2015
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (71 listed products contain Everolimus). The latest listed patent expires 1 Jul 2028. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Everolimus is an mTOR inhibitor and derivative of Sirolimus, used in the treatment of various types of cancer and in preventing organ transplant rejection. It acts by inhibiting the mammalian target of rapamycin (mTOR) pathway, which is involved in cell proliferation, angiogenesis, and metabolism.
Chemical identity
- IUPAC name
- (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
- Canonical SMILES
- C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC
- InChIKey
- HKVAMNSJSFKALM-GKUWKFKPSA-N
- Synonyms
- Afinitor API, 42-o-(2-hydroxyethyl)rapamycin, afinitor, certican, rad 666, rad-001, rad-666, rad001, rapamycin, 42-o-(2-hydroxyethyl)-, sdz rad, sdz-rad, votubia
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Kinase Inhibitor; mTOR Inhibitor Immunosuppressant
- Mechanism of action
- Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A4 Inhibitors; mTOR Inhibitors; Protein Kinase Inhibitors
- Physiologic effect
- Decreased Immunologic Activity
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Everolimus?
12 organisations hold an active US FDA Type II Drug Master File or a CEP for Everolimus: Biocon Limited (India), BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD (China), FARMHISPANIA SA (Spain), CHENGDU YACHT BIO-TECHNOLOGY CO LTD (China), CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD, CKD BIO CORP (South), CONCORD BIOTECH LTD (India) and HANGZHOU HUADONG MEDICINE GROUP KANGRUN PHARMACEUTICAL CO LTD (China), and 4 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Everolimus Drug Master Files are active?
Biocon Limited (DMF 29657, 31950), BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD (DMF 32020, 36661), FARMHISPANIA SA (DMF 34295, 42323), CHENGDU YACHT BIO-TECHNOLOGY CO LTD (DMF 29405, 39361), CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD (DMF 27216), CKD BIO CORP (DMF 34106), CONCORD BIOTECH LTD (DMF 26350) and HANGZHOU HUADONG MEDICINE GROUP KANGRUN PHARMACEUTICAL CO LTD (DMF 26738) and 2 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Everolimus records mean?
1 organisation has only inactive Type II DMFs for Everolimus. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Everolimus have a European Certificate of Suitability?
Yes. 8 organisations hold a valid CEP for Everolimus on the EDQM register, including HISUN PHARMACEUTICAL (HANGZHOU) CO., LTD. Hangzhou City (CN), FARMHISPANIA S.A. Montmeló (ES), CONCORD BIOTECH LIMITED Ahmedabad (IN), SYNTHON B.V. Nijmegen (NL), Chunghwa Chemical Synthesis & Biotech Co., Ltd. Shu-Lin (TW) and BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. Suzhou (CN) and 2 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
Does the FDA Orange Book list patents for products containing Everolimus?
Yes. The latest patent listed for an approved US product containing Everolimus expires 1 Jul 2028, across 71 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Everolimus supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Everolimus?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.